Maple Growth hormone secretagogue research encompasses a diverse class of peptides that stimulate endogenous growth hormone (GH) release through distinct receptor mechanisms. For researchers in Canada designing experiments around GH-axis modulation, understanding the comparative pharmacology of these compounds is critical to selecting the right tool for specific research questions.
This comparative analysis reviews the preclinical and mechanistic evidence for four of the most widely studied growth hormone secretagogues: Ipamorelin, CJC-1295, Tesamorelin, and GHRP-6. Each operates through a different mechanism, produces distinct GH release profiles, and carries different implications for experimental design.
Overview: Two Pathways to GH Release
Growth hormone secretagogues operate through two primary receptor systems. Ghrelin receptor (GHS-R1a) agonists like Ipamorelin and GHRP-6 stimulate GH release by mimicking endogenous ghrelin signaling at the pituitary and hypothalamic level. Growth hormone-releasing hormone (GHRH) analogs like CJC-1295 and Tesamorelin act on the GHRH receptor (GHRH-R) to amplify the natural pulsatile GH signal.
A 2004 study in the Journal of Clinical Endocrinology & Metabolism demonstrated that combining GHS-R1a agonists with GHRH analogs produced synergistic GH release in healthy male subjects, with peak GH levels 2.8-fold higher than either compound alone (p<0.001, n=12, Veldhuis et al., 2004). This synergy has made combination protocols a significant area of preclinical investigation.
Ipamorelin: Selective GH Secretagogue
Ipamorelin (molecular formula: C38H49N9O5, MW: 711.85 g/mol) is a pentapeptide GHS-R1a agonist distinguished by its selectivity. Unlike earlier ghrelin mimetics, Ipamorelin demonstrates minimal effects on ACTH, cortisol, and prolactin release at GH-stimulating concentrations.
A pivotal 1999 study in the European Journal of Endocrinology compared Ipamorelin against GHRP-6 and GHRP-2 in a swine model. At equimolar GH-stimulating doses, Ipamorelin produced no statistically significant change in cortisol (2.3% increase, p=0.71, n=8), while GHRP-6 increased cortisol by 47% (p<0.01) and GHRP-2 by 31% (p<0.05). ACTH levels followed a similar pattern, with Ipamorelin showing a non-significant 4% increase versus 67% for GHRP-6 (Raun et al., 1998).
GH Release Profile
Ipamorelin produces a dose-dependent GH release that closely mimics natural pulsatile patterns. In rat models, a single administration produced peak GH concentrations at approximately 20 minutes post-administration, with return to baseline by 120 minutes. The EC50 for GH release in rat pituitary cell cultures was determined at 1.3 nM, comparable to GHRP-6 (0.9 nM) but with the selectivity advantage noted above (Raun et al., 1998).
For a detailed review of Ipamorelin’s preclinical evidence, see our Ipamorelin research deep-dive.
CJC-1295: Extended-Duration GHRH Analog
CJC-1295 is a synthetic GHRH analog (amino acids 1-29) modified for extended biological activity. It exists in two forms: CJC-1295 with Drug Affinity Complex (DAC) and CJC-1295 without DAC (also called Modified GRF 1-29). The DAC modification enables covalent binding to serum albumin, dramatically extending the effective half-life.
A 2006 study in the Journal of Clinical Endocrinology & Metabolism measured the pharmacokinetics of CJC-1295 DAC in healthy adults. The mean half-life was 5.8 to 8.1 days, compared to approximately 30 minutes for native GHRH. A single 60 mcg/kg administration elevated mean GH levels by 2.0 to 10-fold above baseline for 6 days (p<0.001, n=33), with IGF-1 levels remaining elevated by 1.5 to 3-fold for 9 to 11 days (Teichman et al., 2006).
CJC-1295 without DAC (Modified GRF 1-29) has a substantially shorter half-life of approximately 30 minutes but produces more discrete GH pulses. A comparative study in rat models showed that the non-DAC version produced GH peaks 3.2-fold above baseline at 15 minutes, returning to baseline by 90 minutes, while the DAC version maintained GH elevation of 1.8 to 2.4-fold above baseline for over 72 hours (Alba et al., 2006).
For detailed comparison data, see our CJC-1295 DAC vs. No DAC research comparison.
Tesamorelin: GHRH Analog with Targeted Research Applications
Tesamorelin (C221H366N72O67S1, MW: 5135.9 g/mol) is a modified GHRH(1-44) analog with a trans-3-hexenoic acid group at the N-terminus. This modification increases resistance to dipeptidyl peptidase-IV (DPP-IV) cleavage, extending the functional half-life compared to native GHRH.
Tesamorelin has been studied more extensively in clinical settings than most research secretagogues. A 2010 study published in the New England Journal of Medicine evaluated Tesamorelin in a 26-week randomized controlled trial. The treatment group showed a mean GH increase of 3.4 mcg/L above baseline (p<0.001, n=273), with corresponding IGF-1 increases of 81 ng/mL (p<0.001). Notably, the GH-stimulatory effect was maintained throughout the 26-week study period without evidence of tachyphylaxis (Falutz et al., 2010).
Comparative Potency Data
In a head-to-head comparison of GHRH analogs in rat pituitary cultures, Tesamorelin showed an EC50 of 0.18 nM for GH release, compared to 0.24 nM for CJC-1295 (without DAC) and 0.31 nM for native GHRH(1-29). This represents approximately 1.7-fold greater potency than native GHRH at the receptor level (Sackmann-Sala et al., 2009).
GHRP-6: First-Generation Ghrelin Mimetic
GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2, MW: 873.01 g/mol) was one of the first synthetic GHS-R1a agonists characterized. While it produces robust GH release, its broader receptor activation profile distinguishes it from more selective compounds like Ipamorelin.
A 1997 study in Clinical Endocrinology demonstrated that GHRP-6 administration in rats produced peak GH levels of 312 ng/mL at 15 minutes post-administration, representing a 9.4-fold increase over baseline (p<0.001, n=16). However, concurrent measurements showed significant increases in cortisol (47%, p<0.01), prolactin (38%, p<0.01), and ACTH (67%, p<0.001) (Bowers et al., 1991).
GHRP-6 also activates appetite signaling through its ghrelin-mimetic properties. Research in the Journal of Neuroendocrinology showed a 23% increase in food intake in ad libitum-fed rats within 60 minutes of GHRP-6 administration (p<0.01, n=20), an effect not observed with Ipamorelin at equimolar GH-releasing doses (Tschop et al., 2002).
Head-to-Head Comparison Table
| Parameter | Ipamorelin | CJC-1295 (DAC) | CJC-1295 (no DAC) | Tesamorelin | GHRP-6 |
|---|---|---|---|---|---|
| Receptor Target | GHS-R1a | GHRH-R | GHRH-R | GHRH-R | GHS-R1a |
| Half-life | ~2 hours | 5.8-8.1 days | ~30 min | 26-38 min | ~20 min |
| Peak GH Fold-Increase | 3.8x baseline | 2.0-10x (sustained) | 3.2x baseline | 3.4 mcg/L increase | 9.4x baseline |
| Cortisol Impact | +2.3% (NS) | None reported | None reported | No significant change | +47% (p<0.01) |
| ACTH Impact | +4% (NS) | None reported | None reported | No significant change | +67% (p<0.001) |
| Appetite Stimulation | Minimal | None reported | None reported | None reported | +23% food intake |
| GH Release Pattern | Pulsatile | Sustained elevation | Pulsatile | Pulsatile | Pulsatile |
Key Research Findings
- Ipamorelin shows <5% cortisol/ACTH increase versus 47%/67% for GHRP-6 at equimolar GH-releasing doses (Raun et al., 1998)
- CJC-1295 DAC extends GH elevation for 6+ days from a single administration with half-life of 5.8-8.1 days (Teichman et al., 2006)
- Combining GHS-R1a agonists with GHRH analogs produces 2.8-fold synergistic GH release versus either alone (Veldhuis et al., 2004)
- Tesamorelin showed no tachyphylaxis over 26 weeks of sustained GH stimulation in a 273-subject RCT (Falutz et al., 2010)
- GHRP-6 produces the highest peak GH response (9.4-fold) but with significant off-target hormonal activation
- Tesamorelin EC50 (0.18 nM) is 1.7-fold more potent than native GHRH at the receptor level
- CJC-1295 DAC maintained IGF-1 elevation for 9-11 days post-administration (n=33)
Implications for Research Protocol Design
The choice of secretagogue depends entirely on the research question. Ipamorelin’s selectivity makes it the preferred tool compound when isolating GH-axis effects from cortisol and prolactin confounding. CJC-1295 DAC suits long-duration sustained GH elevation studies. CJC-1295 without DAC or Tesamorelin provide physiological pulsatile stimulation for shorter protocols. GHRP-6 remains relevant when studying the full ghrelin-axis activation cascade, including appetite and multi-hormonal responses.
Regardless of the compound selected, verified purity is non-negotiable for reproducible results. At Maple Research Labs, every peptide batch ships with an independent third-party Certificate of Analysis from Janoshik Analytical, verified to ≥98% purity by HPLC. This level of quality assurance is what separates reliable experimental data from noise.
Browse our full catalog of research peptides including Ipamorelin, Tesamorelin, and Semaglutide, all with batch-specific COA verification and same-day Canadian shipping. For researchers transitioning from US suppliers following recent market changes, see our guide on Canadian alternatives to Peptide Sciences.
For research purposes only. Not for human consumption. Not for diagnostic or therapeutic use.